

EMA/256028/2019

European Medicines Agency decision

P/0194/2019

of 15 May 2019

on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (EMA-002064-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0194/2019

of 15 May 2019

on the acceptance of a modification of an agreed paediatric investigation plan for gilteritinib (as fumarate) (EMA-002064-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0006/2018 issued on 19 January 2018,

Having regard to the application submitted by Astellas Pharma Europe B.V. on 21 December 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 March 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for gilteritinib (as fumarate), film-coated tablet, age-appropriate oral dosage form, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE - Leiden, The Netherlands.

EMA/PDCO/6646/2019
Amsterdam, 29 March 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002064-PIP01-16-M01

Scope of the application

Active substance(s):

Gilteritinib (as fumarate)

Condition(s):

Treatment of acute myeloid leukaemia

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Astellas Pharma Europe B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Astellas Pharma Europe B.V. submitted to the European Medicines Agency on 21 December 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0006/2018 issued on 19 January 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 29 January 2019.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of acute myeloid leukaemia

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- film-coated tablet, oral use, age-appropriate oral dosage form, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition

Treatment of acute myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of patients from 6 months to less than 18 years of age with relapsed or refractory FLT3/ITD positive acute myeloid leukaemia or newly-diagnosed FLT3/ITD positive acute myeloid leukaemia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of film-coated tablets smaller and of lower strength (compared to the existing pharmaceutical form) and suitable to be administered as oral suspension and appropriate to children unable to swallow the adult-sized film-coated tablets.
Non-clinical studies	1	Study 2 Definitive juvenile rat study aimed to assess the toxicity of gilteritinib.

Clinical studies	2	Study 3 Open-label, single arm study to evaluate the pharmacokinetic, safety and anti-tumour activity of gilteritinib used in sequential combination with chemotherapy in paediatric patients from 6 months to less than 18 years of age (and young adults) with FLT3/ITD positive relapse/refractory acute myeloid leukaemia with a dose-finding phase (phase 1) and an expansion phase (phase 2) (2215-CL-0603) Study 4 Open-label, single arm study to evaluate the pharmacokinetic, safety and efficacy of gilteritinib used in sequential combination with chemotherapy in paediatric patients from 6 months to less than 18 years of age (and young adults) with FLT3/ITD positive newly-diagnosed acute myeloid leukaemia (2215-CL-0604-gilteritinib in combination with standard chemotherapy arm)
Extrapolation, modelling and simulation studies	1	Study 5 Modelling and simulation study to simulate and predict gilteritinib exposure in children from 6 months to less than 18 years of age with acute myeloid leukaemia.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes